A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
NCT ID: NCT06810505
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
420 participants
INTERVENTIONAL
2025-02-13
2031-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Atogepant is a medicine currently approved in the United States and Europe for the preventive treatment of migraine in adult patients with migraine and is being studied for the preventative treatment of chronic migraine in participants between the ages of 12 and 17 years. Participants will be randomly assigned to one of the 2 groups to be treated with either atogepant or placebo. This study is double-blinded, which means that neither the patients nor the study doctors know who is given which study treatment. Approximately 420 participants 12 to 17 years of age with chronic migraine will be enrolled at approximately 70 sites across the world.
Participants will receive oral tablets of atogepant or placebo once daily for 12 weeks and will be followed for 4 weeks.
Participants will attend regular visits during the study at a hospital or clinic and the effects of treatment will be checked by completion of a daily diary, medical assessments, blood tests, checking for side effects, and completing questionnaires.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Atogepant
Participants will receive atogepant once daily for 12 weeks.
Atogepant
Oral tablet
Placebo for Atogepant
Participants will receive placebo for atogepant once daily for 12 weeks.
Placebo for Atogepant
Oral tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atogepant
Oral tablet
Placebo for Atogepant
Oral tablet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* During the last 28 days of the screening/baseline period, and as per eDiary:
* Participant must have completed the eDiary for a minimum of 20 out of 28 days.
* Participant has \>= 15 headache days.
* Participant has \>= 8 migraine days.
Exclusion Criteria
* History of any clinically significant hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, cardiovascular or neurologic disease.
12 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rehabilitation & Neurological Services /ID# 270782
Huntsville, Alabama, United States
Preferred Research Partner, Inc /ID# 270389
Little Rock, Arkansas, United States
Preferred Research Partners /ID# 270419
Little Rock, Arkansas, United States
Advanced Research Center /ID# 270257
Anaheim, California, United States
Neuro Pain Medical Center /ID# 271048
Fresno, California, United States
Accellacare - Long Beach /ID# 270398
Long Beach, California, United States
Excell Research /ID# 270258
Oceanside, California, United States
Sunwise Clinical Research /ID# 270431
Walnut Creek, California, United States
Northwest Florida Clinical Research Group, LLC /ID# 270833
Gulf Breeze, Florida, United States
Auzmer Research /ID# 271158
Lakeland, Florida, United States
My Preferred Research /ID# 270312
Miami, Florida, United States
Encore Medical Research - Weston /ID# 271139
Weston, Florida, United States
Deaconess Midtown Hospital /ID# 270572
Evansville, Indiana, United States
Michigan Headache & Neurological Institute /ID# 270942
Ann Arbor, Michigan, United States
Proven Endpoints LLC /ID# 270269
Ridgeland, Mississippi, United States
Cct Research - Papillion Research Center /ID# 270393
Papillion, Nebraska, United States
Healthy Perspectives - Innovate Mental Health Services /ID# 270847
Nashua, New Hampshire, United States
Dent Neurologic Institute - Amherst /ID# 270260
Amherst, New York, United States
Headache Wellness Center /ID# 270568
Greensboro, North Carolina, United States
Frontier Clinical Research - Scottdale /ID# 270854
Scottdale, Pennsylvania, United States
Frontier Clinical Research - Smithfield /ID# 270849
Smithfield, Pennsylvania, United States
Access Clinical Trials Inc /ID# 270280
Nashville, Tennessee, United States
UT Health Austin at Dell Childrens Neurology Clinic /ID# 270577
Austin, Texas, United States
Earle Research /ID# 270424
Houston, Texas, United States
Clinpoint Trials /ID# 270261
Waxahachie, Texas, United States
Pantheon Clinical Research /ID# 270259
Bountiful, Utah, United States
Highland Clinical Research /ID# 270281
Salt Lake City, Utah, United States
Frontier Clinical Research - Kingwood /ID# 271053
Kingwood, West Virginia, United States
London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 270659
London, Ontario, Canada
McGill University Health Centre - Glen Site /ID# 270662
Montreal, Quebec, Canada
Herlev Hospital /ID# 270482
Herlev, Capital Region, Denmark
Regionshospitalet Godstrup /ID# 270481
Herning, Central Jutland, Denmark
Semmelweis Egyetem /ID# 271219
Budapest, , Hungary
Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 270756
Milan, Milano, Italy
Konan Medical Center /ID# 270486
Kobe, Hyōgo, Japan
Umenotsuji Clinic /ID# 270484
Kochi, Kochi, Japan
Tominaga Clinic - Osaka /ID# 270483
Osaka, Osaka, Japan
Tokyo Headache Clinic /ID# 271610
Shibuya-ku, Tokyo, Japan
Tokyo Medical University Hospital /ID# 270487
Shinjuku-ku, Tokyo, Japan
Tendo Brain Clinic /ID# 271410
Tendo-shi, Yamagata, Japan
Nagaseki Headache Clinic /ID# 271699
Kai, Yamanashi, Japan
Tanaka Neurosurgery & Headache Clinic /ID# 271346
Kagoshima, , Japan
Canisius-Wilhelmina Ziekenhuis /ID# 270374
Nijmegen, Gelderland, Netherlands
HagaZiekenhuis /ID# 270379
The Hague, South Holland, Netherlands
Clinical Research Center Medic-R /ID# 270235
Poznan, Greater Poland Voivodeship, Poland
Athleticomed Sp. z o.o /ID# 270243
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Specjalistyczne Gabinety Sp. z o.o /ID# 270238
Krakow, Lesser Poland Voivodeship, Poland
MIGRE Polskie Centrum Leczenia Migreny /ID# 270239
Wroclaw, Lower Silesian Voivodeship, Poland
OHA-MED sp. z o.o /ID# 270242
Warsaw, Masovian Voivodeship, Poland
CMRC Headlands LLC /ID# 271300
San Juan, , Puerto Rico
Medway Maritime Hospital /ID# 271885
Gillingham, Kent, United Kingdom
Royal Aberdeen Children's Hospital /ID# 271664
Aberdeen, Scotland, United Kingdom
Stepping Hill Hospital-Stockport NHS foundation trust /ID# 271883
Stockport, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Site Coordinator
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-513836-28
Identifier Type: -
Identifier Source: secondary_id
M23-712
Identifier Type: -
Identifier Source: org_study_id